Healthcare [ 10/13 ] | Biotechnology [ 87/159 ]
NASDAQ | Common Stock
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.
It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | -0.03 Increased by +83.33% | -0.14 Increased by +78.57% |
| Mar 12, 24 | -0.19 Decreased by -5.56% | -0.16 Decreased by -18.75% |
| Nov 2, 23 | -0.09 Decreased by -50% | -0.17 Increased by +47.06% |
| Aug 3, 23 | -0.08 Increased by +68% | -0.18 Increased by +55.56% |
| May 4, 23 | -0.18 Increased by +33.33% | -0.22 Increased by +18.18% |
| Feb 28, 23 | -0.18 Increased by +28% | -0.27 Increased by +33.33% |
| Nov 3, 22 | -0.06 Increased by +84.62% | -0.17 Increased by +64.71% |
| Aug 4, 22 | -0.25 Increased by +32.43% | -0.22 Decreased by -13.64% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 48.07 M Increased by +39.71% | -10.75 M Increased by +58.98% | Decreased by -22.36% Increased by +70.64% |
| Dec 31, 23 | 45.09 M Increased by +58.59% | -26.88 M Decreased by -3.18% | Decreased by -59.6% Increased by +34.94% |
| Sep 30, 23 | 54.52 M Decreased by -2.27% | -13.45 M Decreased by -49.59% | Decreased by -24.67% Decreased by -53.06% |
| Jun 30, 23 | 41.49 M Increased by +47.19% | -11.49 M Increased by +67.64% | Decreased by -27.7% Increased by +78.02% |
| Mar 31, 23 | 34.41 M Increased by +59.12% | -26.21 M Increased by +30.36% | Decreased by -76.16% Increased by +56.23% |
| Dec 31, 22 | 28.43 M Increased by +21.5% | -26.05 M Increased by +21.84% | Decreased by -91.6% Increased by +35.67% |
| Sep 30, 22 | 55.78 M Increased by +280.3% | -8.99 M Increased by +82.11% | Decreased by -16.12% Increased by +95.3% |
| Jun 30, 22 | 28.19 M Increased by +325.85% | -35.52 M Increased by +24.45% | Decreased by -125.98% Increased by +82.26% |